Iovance Biotherapeutics Inc (IOVA)

[GMH*]

The vast majority of Q&A was trying to get a handle on how to model patient flow / flows to try and model out Q2 revenue. It will be interesting to see how the revenue projections are updated over the next weeks. Think analysts were caught off guard on the ramp since revenue estimates implied around 65 patients.

Just re-listening to the call. It is hilarious at how each analyst just tries to just re-frame the same patient question.